Novo Nordisk’s stock that trades in the United States rose 4.2% after the Danish company said U.S. regulators approved its Wegovy drug as part of a treatment for a liver disease found in many ...

Investors eyed risks around a high-stakes US-Ukraine meeting, kicking off a week dominated by a Federal Reserve speech that ...

Canada's main stock index opened lower on Monday as investors reined in big bets, kicking off a busy week featuring Ukraine ...

Dow Jones Top Company Headlines at 3 PM ET: White House in Talks With Intel for 10% U.S. Government Stake | Air ... White House in Talks With Intel for 10% U.S. Government Stake Money earmarked for ...

Wall Street is holding near its records ahead of a week likely to be dominated by updates from the head of the Federal ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.Semaglutide 2.4 mg injection (Wegovy ...

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

Who benefits? The reduced price applies to self-paying patients—those without insurance, or whose insurance doesn’t cover ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...